Related Experiment Video
Updated: Jan 7, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Association Between Psychiatric Comorbidity and Retention in Substance Use Disorder Treatment: Results From
Himani Byregowda1, Masoumeh Amin-Esmaeili1, Ryoko Susukida1
1Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract:
Objective: To examine the association of comorbid mood and/or anxiety disorders (M/AD) and psychological distress (PD) with treatment retention in substance use disorder (SUD) trials. Methods: Data are from 21 NIDA-sponsored randomized controlled trials (RCTs) for SUDs (n = 5,404). M/AD was assessed using the DSM-IV criteria and PD was assessed using the Addiction Severity Index. Treatment retention was defined as trial completion based on last visit attendance. Analyses used doubly-robust multivariable logistic regression with propensity score weighting. Results: Average treatment retention was 71.8%. Comorbid M/AD was associated with higher odds of treatment retention in pharmacological trials of cocaine and methamphetamine use disorder. However, comorbid PD was associated with lower treatment retention in behavioral trials of any stimulant use disorders and higher retention in pharmacological trials of methamphetamine use disorder. Conclusion: M/AD is associated with better treatment retention in SUD trials, while PD's effects depend on treatment type and trial target substance.
More Related Videos
Related Concept Videos
Drug Therapy
Antianxiety Medications
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Drug Abuse and Addiction: Pharmacological Phenomena
Psychosis: Goals of Pharmacotherapy
Psychological and Sociocultural Causes of Schizophrenia
Drug Dependence

